AMT-101 is an orally deliverable IL-10-cholix fusion protein [1
]. It combines the anti-inflammatory IL-10 with a nontoxic fragment of the cholix exotoxin from Vibrio cholerae
. The exotoxin fragment facilitates delivery of the fusion protein selectively to the intestinal epithelium via
transcytosis through intestinal enterocytes into the lamina propria, where it is intended to treat intestinal inflammatory diseases. IL-10 treatment is associated with dose limiting systemic toxicities including anemia and thrombocytopenia. AMT-101 was designed to overcome this limitation by restricting its IL-10 activity to within the GI tract.